SMS Pharmaceuticals Limited — Investor Meet, 05-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

SMS Pharmaceuticals reported FY25 revenue up 10% to INR783 Cr and PAT up 39% to INR69 Cr, driven by volume growth, improved product mix, and cost efficiencies from backward integration. Q4 revenue jumped 43% YoY to INR248 Cr with gross margin at 30% and EBITDA margin at 16%. Key growth in anti-inflammatory (+22%), ARV (+15%), anti-epileptic (+106%), and anti-diabetic (+5%) segments. Backward integration projects are commercializing, expected to improve margins from Q2 FY26. Management aims for 20% revenue growth and 20% EBITDA margin in FY26, supported by INR250 Cr capex for capacity and new products, including CMO. Ibuprofen volumes nearly doubled (~5,000 MT), with regulated markets share targeting 70%. Capacity utilization steady at 75-80%, with confident outlook on scale and diversification driving growth.